Welcome to Outsourcing-Pharma.com’s round-up of CRO focused partnerships and collaborations including news from Particle Science and Agility Clinical Partners.
Pennsylvania-based CRO (contract research organization) Particle Science will give its clients access to pharmaceutical nanomilling equipment thanks to a partnership with NETZSCH Premier Technologies.
Described as “one of the premier systems for pharmaceutical applications” by Dr. Robert Lee, Vice President Pharmaceutical Development at Particle Science in a press statement, the NETZSCH Deltavita Mill will feed growing customer demand for wet-milled products including 20 projects the CRO is currently working on.
NETZSCH’s President said, regarding Particle Science: “They will be a valuable partner to fully demonstrate the utility of our equipment and we will work with them as they continue to expand.”
The news comes just days Particle Science teamed up with Crystal Pharmatech , in a partnership which will see the Chinese CRO analyse the bioavailability and material properties compounds being developed by the US firm's customers.
To continue the CRO chain, Crystal is close to partnering 3D BioOptima for pharmacokinetic and pharmacodynamics modeling.
California-based orphan drug developer Agility Clinical has announced a partnership with Dutch CRO PSR Orphan Experts. The deal will provide clients of both companies orphan drug development services in both Europe and the US.
Agility CEO Ellen Morgan expressed her excitement in the mutually beneficial deal adding: “With few CROs focused on rare diseases, partnering with another like company to share knowledge and experiences strengthens our services to clients, and our reach."
Finally, Cliantha Research Partners – a global CRO with headquarters in India – has announced it will partner with global technology provider Acceliant and will use Acceliant’s eClinical Suite platform in order to manage its clinical data.
Hitesh Chauhan, Associate Director of Biometrics at Cliantha, cited ease of use as a major reason for choosing Acceliant’s technology and believes the deal will “drive efficiency, lower costs and accelerate clinical trial studies.”